GSK2668176

GSK2668176 is a potent, small molecule active moiety that results from the rapid in vivo breakdown of the phosphate ester pro-drug **GSK2983559**, developed to improve solubility and exposure[1][3]. GSK2668176 was investigated in first-in-human clinical trials, where its pharmacokinetics (including plasma concentration, maximum concentration (C_{max}), time to maximum concentration (T_{max}), and terminal half-life (t_{1/2})) were characterized in healthy participants[1][3]. There is no publicly disclosed mechanism of action or targeted indication from the available trial documentation, suggesting the program was in early stage exploratory development.